肾性贫血的诊治进展

doi:10.16138/j.1673-6087.2021.01.003

摘要/Abstract

关键词: 慢性肾脏病, 肾性贫血, 铁剂, 红细胞生成刺激因子, 罗沙司他

中图分类号:

R692

陈晓农, 高琛妮. 肾性贫血的诊治进展[J]. 内科理论与实践, 2021, 16(01): 10-14.

参考文献 41

[1]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822. doi: 10.1016/S0140-6736(12)60033-6 URL
[2]	Kidney Disease: Improving Global Outcomes KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease[J]. Kidney Int Suppl, 2012, 2(4):279-335. doi: 10.1038/ki.1972.107 URL
[3]	World Health Organization. Iron deficiency anemia:assessment, prevention and control[G/OL]. 2001. https://www.who.int/nutrition/publications/en/ida_assessment_ prevention_control.pdfhttps://www.who.int/nutrition/publications/en/ida_assessment_ prevention_control.pdf.
[4]	中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2018修订版)[J]. 中华肾脏病杂志, 2018, 34(11):860-866. doi: 10.3760/cma.j.issn.1001-7097.2018.11.012
[5]	Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study[J]. Medicine (Baltimore), 2016, 95(24): e3872. doi: 10.1097/MD.0000000000003872 URL
[6]	束金莲, 李贺, 姚少峰, 等. 初始血液透析患者贫血的相关危险因素回顾性研究[J/OL]. 中国现代医学杂志, 2020. https://kns.cnki.net/kcms/detail/43.1225.R.20200707.1308.024.html
[7]	Zhou QG, Jiang JP, Wu SJ, et al. Current pattern of Chinese dialysis units: a cohort study in a representative sample of units[J]. Chin Med J (Engl), 2012, 125(19): 3434-3439.
[8]	Zuo L, Wang M, Hou F, et al. Anemia management in the China dialysis outcomes and practice patterns study[J]. Blood Purif, 2016, 42(1): 33-43. doi: 10.1159/000442741 URL
[9]	Ni Z, Jin H, Jiang G, et al. A telemedicine-based registration system for the management of renal anemia in patients on maintenance hemodialysis: multicenter study[J]. J Med Internet Res, 2019, 21(5): e13168. doi: 10.2196/13168 URL
[10]	Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia[J]. BMC Nephrol, 2016, 17(1): 97. doi: 10.1186/s12882-016-0312-9 pmid: 27460779
[11]	Hazin MAA. Anemia in chronic kidney disease[J]. Rev Assoc Med Bras (1992), 2020, 66 Suppl 1: s55-s58.
[12]	王莉君, 袁伟杰. 关于肾性贫血治疗相关指南与共识回顾[J]. 中国血液净化, 2018, 17(1): 1-5.
[13]	Covic A, Jackson J, Hadfield A, et al. Real-world impact of cardiovascular disease and anemia on quality of life and productivity in patients with non-dialysis-dependent chronic kidney disease[J]. Adv Ther, 2017, 34(7): 1662-1672. doi: 10.1007/s12325-017-0566-z URL
[14]	Ganz T, Aronoff GR, Gaillard CAJM, et al. Iron administration, infection, and anemia management in CKD: untangling the effects of intravenous iron therapy on immunity and infection risk[J]. Kidney Med, 2020, 2(3): 341-353. doi: 10.1016/j.xkme.2020.01.006 URL
[15]	Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(2): e0117383. doi: 10.1371/journal.pone.0117383 URL
[16]	Gafter-gvili A, Schechter A, Rozen-zvi B. Iron deficiency anemia in chronic kidney disease[J]. Acta Haematol, 2019, 142(1): 44-50. doi: 10.1159/000496492 URL
[17]	Shepshelovich D, Rozen-Zvi B, AVNI T, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis[J]. Am J Kidney Dis, 2016, 68(5): 677-690. doi: S0272-6386(16)30125-1 pmid: 27321965
[18]	Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis[J]. N Engl J Med, 2019, 380(5): 447-458. doi: 10.1056/NEJMoa1810742 URL
[19]	Wyatt CM, Drueke TB. High-dose Ⅳ iron for anemia correction in chronic kidney disease[J]. Kidney Int, 2019, 95(4): 727-730. doi: 10.1016/j.kint.2019.01.013 URL
[20]	Lewis JB, Sika M, Koury MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis[J]. J Am Soc Nephrol, 2015, 26(2): 493-503. doi: 10.1681/ASN.2014020212 URL
[21]	Collister D, Rigatto C, Tangri N. Anemia management in chronic kidney disease and dialysis: a narrative review[J]. Curr Opin Nephrol Hypertens, 2017, 26(3): 214-218. doi: 10.1097/MNH.0000000000000317 URL
[22]	Womack R, Berru F, Panwar B, et al. Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a ran-domized trial[J]. Clin J Am Soc Nephrol, 2020, 5(9):1251-1258.
[23]	Sakaguhi Y, Hamano T, Wada A, et al. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis[J]. J Am Soc Nephrol, 2019, 30(6): 1037-1048. doi: 10.1681/ASN.2018101007 URL
[24]	Thavarajah S, Choi MJ. The use of erythropoiesis-stimulating agents in patients with CKD and cancer: a clinical approach[J]. Am J Kidney Dis, 2019, 74(5): 667-674. doi: S0272-6386(19)30767-X pmid: 31395400
[25]	René É, Lazrak HH, Laurin LP, et al. Association of erythropoiesis-stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a ne-sted case-control study[J]. Nephrol Dial Transplant, 2017, 32(6): 1047-1052.
[26]	马红珍. 慢性肾脏病肾性贫血的治疗策略[J]. 浙江医学, 2020, 42(11): 1103-1105.
[27]	陈楠. 罗沙司他在慢性肾脏病患者肾性贫血治疗中的应用[J]. 中华内科杂志, 2019, 58(12): 919-920.
[28]	Chen N, Hao C, Liu BC, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Eng J Med, 2019, 381(11):1011-1022. doi: 10.1056/NEJMoa1901713 URL
[29]	Chen N, Hao C, Liu BC, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. doi: 10.1056/NEJMoa1813599 URL
[30]	Akizawa T, Yamaguchi Y, Otsuka T, et al. A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naïve chronic kidney disease patients not on dialysis[J]. Nephron, 2020, 144(8): 372-382. doi: 10.1159/000508100 URL
[31]	Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan[J]. J Am Soc Nephrol, 2020(7): 1628-1639. doi: 10.1681/ASN.2019060623 pmid: 32493693
[32]	Zheng Q, Yang H, Fu X, et al. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis[J]. Nephrol Dial Transplant, 2020. [Epub ahead of print].
[33]	Akizawa T, Nangaku M, Yonekawa T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a ran-domized, double-blind, phase 3 trial[J]. Clin J Am Soc Nephrol, 2020, 15(8): 1155-1165. doi: 10.2215/CJN.16011219 URL
[34]	Nangaku M, Kondo K, Takabe S, et al. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: a phase 3 open-label study in Japan[J]. Ther Apher Dial, 2020. [Epub ahead of print].
[35]	Akizawa T, Taguchi M, Matsuda Y, et al. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase Ⅲ studies[J]. BMJ Open, 2019, 9(6): e026602. doi: 10.1136/bmjopen-2018-026602 URL
[36]	Yamamoto H, Taguchi M, Matsuda Y, et al. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies[J]. BMJ Open, 2019, 9(6): e026704. doi: 10.1136/bmjopen-2018-026704 URL
[37]	Agarwal AK, Yee J. Hepcidin[J]. Adv Chronic Kidney Dis, 2019, 26(4): 298-305. doi: 10.1053/j.ackd.2019.04.005 URL
[38]	Roth MP, Meynard D, Coppin H. Regulators of hepcidin expression[J]. Vitam Horm, 2019, 110: 101-129.
[39]	Renders L, Budde K, Rosenberger C, et al. First-in-human Phase Ⅰ studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis[J]. PLoS One, 2019, 14(3): e0212023. doi: 10.1371/journal.pone.0212023 URL
[40]	Voors-pette C, Lebozec K, Dogterom P, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-ferroportin antibody in patients with anemia due to chronic renal failure[J]. Blood, 2016, 128 (Suppl 4): 1280. doi: 10.1182/blood.V128.22.1280.1280 URL
[41]	Katsarou A, Pantopoulos K. Hepcidin therapeutics[J]. Pharmaceuticals(Basel), 2018, 11(4): 127.

肾性贫血的诊治进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	章晓炎, 徐静, 璩斌. 血清维生素D水平对老年慢性肾脏病患者肾功能的影响[J]. 内科理论与实践, 2022, 17(04): 307-312.
[2]	轩应利, 陈斐虹, 秦丽, 和瑞斌, 庞诗情, 袁江姿. 维生素D与慢性肾脏病患者夜间血压的相关性分析[J]. 内科理论与实践, 2021, 16(04): 246-250.
[3]	杨聚荣, 林利容. 慢性肾脏病患者妊娠的管理现状及策略[J]. 诊断学理论与实践, 2021, 20(02): 125-129.
[4]	范秋灵. 糖尿病肾病和非糖尿病慢性肾脏病患者应用钠-葡萄糖协同转运蛋白2抑制剂：预后评估及相关指南解读[J]. 诊断学理论与实践, 2021, 20(02): 130-137.
[5]	晏焕青, 谢琼虹, 尚达, 戴淑琪, 朱彤莹. 胎球蛋白A对腹膜透析患者冠状动脉钙化发生起始的影响因素分析[J]. 内科理论与实践, 2021, 16(01): 49-52.
[6]	余舒文, 方正滢, 谢静远. 基因检测在慢性肾脏病诊治中的应用及进展[J]. 诊断学理论与实践, 2020, 19(06): 613-617.
[7]	李贵森. 2019年《中国慢性肾脏病矿物质和骨异常诊治指南》解读[J]. 诊断学理论与实践, 2020, 19(03): 229-231.
[8]	李娅, 徐静, 张春丽, 王朝晖, 王伟铭,. IgA肾病患者清晨高血压与肾功能关系的研究[J]. 内科理论与实践, 2020, 15(01): 45-48.
[9]	毕宇芳,. 2型糖尿病合并慢性肾脏病患者口服降糖药治疗中国专家共识（2019年更新版）解读[J]. 内科理论与实践, 2019, 14(06): 333-336.
[10]	王媛媛, 范秋灵. 血清降钙素原在慢性肾脏病合并细菌感染患者中的临床价值[J]. 诊断学理论与实践, 2019, 18(03): 353-359.
[11]	王红鹰, 黄骏文, 邹强, 陈靖, 张敏敏, 张炜晨, 劳正胤. 甲状旁腺全切除加前臂自体移植术治疗肾性继发性甲状旁腺功能亢进的长期疗效[J]. 外科理论与实践, 2018, 23(06): 523-527.
[12]	陈晓农, 汪知玉,. 新型骨相关生物标志物在慢性肾脏病血管钙化中的应用价值[J]. 内科理论与实践, 2018, 13(04): 202-206.
[13]	张春燕, 汪知玉, 杨俪, 黄晓敏, 施咏梅, 王朝晖, 任红, 陈晓农,. “学校式”磷教育在腹膜透析高磷患者中的运用[J]. 内科理论与实践, 2018, 13(04): 227-230.
[14]	赵雪, 陈丽萌,. 慢性肾脏病矿物质和骨异常患者骨折风险评估及临床意义[J]. 内科理论与实践, 2018, 13(04): 244-249.
[15]	田滨瑶, 徐天华, 姚丽,. 继发性甲状旁腺功能亢进的治疗与进展[J]. 内科理论与实践, 2018, 13(04): 250-254.